Target organ status and serum lipids were investigated in white coat h
ypertension in comparison with sustained hypertension and normotension
. We selected three groups balanced for sex, age, body mass index, and
smoking habit: 50 sustained hypertensives (clinical hypertension and
24-hour ambulatory blood pressure >135/85 mm Hg, a cutoff limit obtain
ed from a normotensive population), 25 white coat hypertensives (clini
cal hypertension and 24-hour ambulatory blood pressure <135/85 mm Hg),
and 25 normotensives. Subjects underwent echocardiographic examinatio
n to assess left ventricular mass index, carotid ultrasonography to ev
aluate intima-media thickness and atherosclerotic plaques, venous occl
usion plethysmography to record minimum forearm vascular resistance, a
nd determinations of serum lipid profile and 24-hour urinary albumin e
xcretion. Compared with sustained hypertensives, the white coat hypert
ensives had significantly lower values of left ventricular mass index
(125.9+/-20 versus 97.6+/-11.5 g/m(2), P<.05), intima-media thickness
(0.85+/-0.18 versus 0.71+/-0.15 mm, P<.05), minimum forearm vascular r
esistance (2.33+/-0.11 versus 2.04+/-0.08 resistance units, P<.05), ur
inary albumin excretion values (15.1+/-13.8 versus 4.45+/-1.45 mg per
24 hours, P<.0001), prevalence of left ventricular hypertrophy (38% ve
rsus 4%, P<.002), intima-media thickening (28% versus 4%, P<.015), and
microalbuminuria (22% versus 0%, P<.015). No significant difference,
however, was observed between the white coat hypertensives and the nor
motensives. Serum lipid profile was similar in the white coat hyperten
sives and in the normotensives. In conclusion, our data demonstrate th
at white coat hypertensives do not show target organ damage and do not
present an unfavorable lipid profile, suggesting that they may be cou
nseled on nonpharmacological therapy and that drug treatment could be
withheld or delayed.